AusCann Group Holdings Limited announced that it has held its Pre-Submission Conference meeting (`PSC') with the U.S Food and Drug Administration, Centre for Veterinary Centre (`FDA-CVM') to discuss the development program and regulatory pathway for CPAT-01 in the United States. AusCann has commenced the design phase for its Phase 2C clinical effectiveness trial and will use the formal feedback from the MOC to finalise its study plan. The purpose of the Phase 2C is to generate final pilot data to inform the design of the Company's Phase 3 pivotal program to support a NADA for the approval of CPAT-01, as a world "first-in-class" U.S FDA registered veterinary medicine.